Opaleye Management as of Sept. 30, 2025
Portfolio Holdings for Opaleye Management
Opaleye Management holds 43 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Harrow Health (HROW) | 26.6 | $188M | 3.9M | 48.18 | |
| Eton Pharmaceuticals (ETON) | 8.8 | $62M | 2.9M | 21.73 | |
| Liquidia Corporation Com New (LQDA) | 8.4 | $60M | 2.6M | 22.74 | |
| Rhythm Pharmaceuticals (RYTM) | 6.6 | $47M | 462k | 100.99 | |
| Immunome (IMNM) | 5.3 | $37M | 3.2M | 11.71 | |
| Sanuwave Health (SNWV) | 5.2 | $37M | 980k | 37.48 | |
| Codexis (CDXS) | 4.4 | $31M | 13M | 2.44 | |
| Tg Therapeutics (TGTX) | 2.7 | $19M | 535k | 36.12 | |
| Ocular Therapeutix (OCUL) | 2.6 | $19M | 1.6M | 11.69 | |
| Cg Oncology (CGON) | 2.3 | $17M | 410k | 40.28 | |
| Stoke Therapeutics (STOK) | 2.3 | $16M | 682k | 23.50 | |
| Apogee Therapeutics (APGE) | 2.0 | $14M | 363k | 39.73 | |
| Alkermes SHS (ALKS) | 1.9 | $14M | 450k | 30.00 | |
| Disc Medicine (IRON) | 1.8 | $13M | 194k | 66.08 | |
| Sarepta Therapeutics (SRPT) | 1.6 | $11M | 585k | 19.27 | |
| Larimar Therapeutics (LRMR) | 1.5 | $11M | 3.7M | 2.84 | |
| Xoma Corp Del Com New (XOMA) | 1.4 | $9.8M | 255k | 38.54 | |
| Rezolute Com New (RZLT) | 1.2 | $8.5M | 903k | 9.40 | |
| Arvinas Ord (ARVN) | 1.2 | $8.4M | 988k | 8.52 | |
| Edgewise Therapeutics (EWTX) | 1.1 | $8.1M | 500k | 16.22 | |
| Annexon (ANNX) | 1.1 | $7.9M | 2.6M | 3.05 | |
| Gossamer Bio (GOSS) | 1.0 | $7.2M | 2.7M | 2.63 | |
| Protagonist Therapeutics (PTGX) | 1.0 | $7.0M | 105k | 66.43 | |
| Journey Med Corp (DERM) | 1.0 | $6.9M | 971k | 7.12 | |
| Sol Gel Technologies Shs New (SLGL) | 0.8 | $6.0M | 205k | 29.15 | |
| Protalix Biotherapeutics (PLX) | 0.8 | $5.7M | 2.6M | 2.22 | |
| Treace Med Concepts (TMCI) | 0.7 | $4.7M | 702k | 6.71 | |
| Revolution Medicines (RVMD) | 0.7 | $4.7M | 100k | 46.70 | |
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 0.7 | $4.6M | 6.0M | 0.77 | |
| Mbx Biosciences (MBX) | 0.6 | $4.4M | 253k | 17.50 | |
| Trevi Therapeutics (TRVI) | 0.5 | $3.6M | 390k | 9.15 | |
| ADC Therapeutics SA SHS (ADCT) | 0.4 | $2.7M | 683k | 4.00 | |
| Alumis (ALMS) | 0.4 | $2.7M | 665k | 3.99 | |
| Cabaletta Bio (CABA) | 0.3 | $1.9M | 809k | 2.34 | |
| Ocuphire Pharma (IRD) | 0.3 | $1.8M | 1.1M | 1.65 | |
| Zymeworks Del (ZYME) | 0.2 | $1.7M | 100k | 17.08 | |
| Spyre Therapeutics Com New (SYRE) | 0.2 | $1.1M | 65k | 16.76 | |
| Rigel Pharmaceuticals (RIGL) | 0.2 | $1.1M | 38k | 28.33 | |
| Alpha Cognition Com New (ACOG) | 0.1 | $750k | 115k | 6.51 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $478k | 317k | 1.51 | |
| Pepgen (PEPG) | 0.0 | $347k | 75k | 4.62 | |
| Ibio Com New (IBIO) | 0.0 | $310k | 375k | 0.83 | |
| Adagio Med Hldgs (ADGM) | 0.0 | $215k | 111k | 1.94 |
